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Background: The prevalence of chronic hepatitis B and C was evaluated some twenty years ago among specific
populations in Guadeloupe. The present study was designed to update these data and determine epidemiological
features of chronic hepatitis B and C infections in the French Caribbean island of Guadeloupe.
Findings: The present study was carried out at the Sainte Genevieve Health and Prevention Center (Guadeloupe),
between May 2006 and July 2007. This is a medical center where patients can attend a free medical check-up paid
for by the Social Security system. Data on hepatitis B (HBV) and C (HCV) status and epidemiological factors were
collected for this study.
A total of 2,200 patients were included in the study. The prevalence of HBV surface antigen was 1.41% (95% CI: 1.0-2.0),
and 0.55% (95% CI: 0.28-0.96) for HCV. The vaccination rate against HBV was 42.0%. HBV transmission was associated
with piercing (12.9%, p = 0.014) and familial exposure (6.4%, p < 0.001) and HCV transmission with gynecological
surgery (50.0%, p = 0.01). The HBV profile was generally hepatitis B e antigen-negative (94.5%). No hepatitis delta was
found. For HCV, genotype 1 was predominant (80%).
Conclusions: This is the first study on the prevalence of HBV and HCV among a general clinic based population in
Guadeloupe and the Caribbean islands. This study reveals that Guadeloupe is an area of low endemicity for HBV and
low HCV prevalence. The reasons for these low prevalence rates are mainly related to the vaccination campaigns
carried out during the past twenty years for HBV and the decrease of nosocomial transmission for HCV.
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Guadeloupe, a French Caribbean island, has geograph-
ical and ethnic specificities, the majority population
being Afro-Caribbean. The most recent scientific data on
the prevalence of viral hepatitis infections in Guadeloupe
were reported by Fest et al. [1,2] in 1993 among blood
donors. They showed that hepatitis B surface antigen
(HBsAg) was present in 3.1%, hepatitis B core antibodies
(anti-HBc) in 22.1% and anti-hepatitis C virus anti-
bodies (anti-HCV) in 0.8% of the population. Except for
Puerto-Rico [3] and Haiti [4], which differ demographically
and socioeconomically from the French Caribbean islands,* Correspondence: moana.simeon@chu-guadeloupe.fr
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distribution, and reproduction in any mediumseroprevalence data in the Caribbean region are scarce.
Some studies have reported HCV genotype distribution in
the Dominican Republic [5] and Puerto-Rico [6], but no in-
formation is available on the seroprevalence of hepatitis B
and C in the Lesser Antilles archipelago.Methods
Study population
The present study was carried out in Guadeloupe, a
French department in the Caribbean, which counts
450,000 inhabitants. The Sainte-Genevieve Health and
Prevention clinic is a social security medical center where
beneficiaries of the health insurance system can attend for
a free medical check-up. The Sainte-Genevieve Center is
the only one Social Security-funded medical center in
Guadeloupe, which is situated in Les Abymes, the principalentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Baseline characteristics of the study population
Characteristic N = 2200 (%)






Working class 508 (23.1)
Farmers 103 (4.7)
Middle/senior management 125 (5.7)
Retired 217 (9.9)
Risk factors
Past surgery 619 (28.1)
Endoscopy 584 (27.5)
Using drugs 13 (0.6)
Intravenously 1 (0.0)
Nasal way 12 (0.6)
Tatoo 216 (10.0)
Piercing 95 (4.4)
Shaving hair or beard 352 (16.3)
Unknown 321 (14.6)
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population). Between May and August 2006 and January
and July 2007, beneficiaries of the French national health
insurance system, aged over 18 years, were invited to
undergo a free health check-up at the Sainte Genevieve
Health and Prevention Center. They were informed of our
study and invited to take part. This check-up included
laboratory analyses and medical tests (vision, hearing,
breathing capacity), supplemented by a physical examin-
ation by a physician. The investigations could be modu-
lated according to items listed on the questionnaire
(independent of our study), which was sent to these
insured individuals when they made their appointments;
these changes depended on the risk factors specific to their
situation. We added serological screening for viral hepatitis
and a questionnaire on the risk factors for hepatitis.
The initial questionnaire containing predetermined
questions on medical history and sociodemographic data
was completed by the patient him/herself. A second pre-
determined medical questionnaire focused on possible
risk factors for HBV and/or HCV infections was then
completed by the medical investigator during a face-to-
face interview.
Our study was performed in accordance with the
Declaration of Helsinki and was approved by a French
Ethics Committee (Comité Consultatif de Protection des
Personnes dans la Recherche Biomédicale) on May 20,
2003, n°03-251. All patients gave their written informed
consent prior to inclusion in the study.
Laboratory analyses
Serological tests for HBV and HCV were performed
on all samples using AxSYM HBsAG (V2) for HBsAg,
AxSYM CORE for anti-HBc, AxSYM AUSAB for anti-
HBs antibodies and AxSYM HCV version 3.0 for anti-
HCV antibodies (Abbott Laboratories, Chicago, IL,
USA). The Monolisa anti-HCV plus (V2) from Biorad
Company was used in the event of any doubtful re-
sults. Delta serology was assessed using the ETI 2AB
deltaK2 kit obtained from Sorin. The tests were per-
formed in strict accordance with the manufacturer’s
instructions.
HBV DNA testing was performed using b-DNA HBV
DNA version 3.0 (limit of detection: 2,000 copies/ml) and
the HCV RNA technique b-DNA HCV RNA version 3.0
(limit of detection: 3,200 copies/ml) (Bayer Laboratories),
according to the manufacturer’s recommendations (Bayer
Diagnostics, Inc.).
HCV genotyping was performed by sequencing the
NS5B region, followed by the phylogenetic analyses as de-
scribed in reference 16. Biochemical tests on liver function
(ALT, γGT), blood counts (hemoglobin, leukocytes), total
cholesterol, triglycerides, serum creatinine and blood sugar
were also performed.Statistical analysis
Statistical data were collected using Epi DATA and ana-
lyzed with STATA and SPSS 11.01. Dichotomous data
were compared using the χ2 test α = 5%, or Fisher’s
exact test when appropriate. Quantitative data were com-
pared using Student’s t test. Exact Poisson confidence
intervals were calculated.
Findings
Baseline characteristics of the study population
In 2006, 8,584 patients were seen at the health center,
compared to 7,156 in 2007. As the investigating phys-
ician was present at the health center every two weeks
in 2007 (versus weekly in 2006), 1,896 patients were eli-
gible in 2006 and 1,576 in 2007. Out of the 3,472 patients
who met the inclusion criteria, informed consent and
complete data were obtained for 2,200 (63.3%) (Table 1).
A significantly higher number of women participated
(59.7% vs. 40.3%, p = 0.001) and the median age was 43
years [18–87]. The majority of the study population were
of low socioeconomic status, the unemployment rate
among them being 56.7%. A history of surgery (28.1%) or
endoscopy (27.5%) was more frequently reported as a
potential source of infection from HBV and/or HCV. The
results of laboratory tests were all available and were
within normal ranges.






N = 14 (%) N = 2186 (%)
Past surgery including 8 (57.1) 611 (27.9) p = 0.02
Gynaecological 7 (50.0) 343 (15.7) p = 0.01
Endoscopy 4 (28.5) 580 (26.5) NS
Tatoo 2 (14.3) 214 (9.8) NS
Shaving 1 (7.1) 351 (16.1) NS
Familial exposure 0 (0.0) 17 (0.8) NS
Using drugs intraveinously 0 (0.0) 1 (0.0) NS
Piercing 0 (0.0) 95 (4.3) NS
Unknown 3 (21.4) 318 (14.5) NS
NS, Not significant.
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A total of 31 patients (1.41%) (95% CI: 1.0%-2.0%) were
positive for HBsAg and 594 (26.5%) (95% CI: 24.7%-
28.4%) were positive for anti-HBc. 12 patients (38.7%) had
PCR-detectable DNA (median value: 4.43 log copies/ml
[3.32-8.00]).
Only 25% of patients had been aware of their sero-
logical status before testing. Most patients (94.5%) were
HBeAg-negative. All subjects who were positive for HBs
antigen were tested for hepatitis delta virus, and 100% of
them were delta negative. The presence of HBsAg was
three to four times more frequent in men than in
women in the 30–39 and 60–69 years age groups. How-
ever, considering the overall HBsAg positive population, no
significant difference between men and women (2.0% vs.
1.1%, NS) was found. HBV transmission was associated
with one, two or three risk factors in 11, 7 and 4 cases re-
spectively, and none in the remaining 9 patients (Table 2).
Among these, piercing (12.9%, p = 0.014), familial exposure
(6.4%, p < 0.001), and a history of surgery or endoscopy
were more frequently reported.
On the other hand, in the population study, the rate of
vaccination against HBV (at least one injection) was
42.7% (95% CI: 40.6%-44.9%). Among them, 56.2% (95%
CI: 54.1%-58.3%) had anti-HBs antibody titers higher
than 20 IU/L.
Chronic hepatitis C
Anti-HCV was detected in 14 out of 2,200 patients
(0.55%; 95% CI: 0.28%-0.96%). The risk factors associ-
ated with HCV transmission are presented in Table 3.
Three out of 14 patients reported no risk factor, while
one or two risk factors were recorded for five and
six patients, respectively (mainly a history of surgery
or endoscopy). HCV-positive serological findings were
significantly associated with previous surgery (57.1%,
p = 0.02). It is noteworthy that two cases of transfusion
were reported.Table 2 Risk factors of chronic hepatitis B transmission
for positive HBsAg patients





N = 31 (%) N = 2169 (%)
Past surgery 12 (38.7) 607 (28.0) NS
Endoscopy 12 (38.7) 572 (26.4) NS
Piercing 4 (12.9) 91 (4.2) p = 0.014
Shaving 4 (12.9) 348 (16.0) NS
Tatoo 3 (9.7) 213 (9.8) NS
Familial exposure 2 (6.4) 33 (1.5) p < 0.001
Using drugs
intraveinously
0 (0.0) 1(0.0) NS
NS, Not significant.Only one patient (7.1%) was aware of his positive sero-
logical status prior to the study. Ten patients (71.4%)
had PCR-detectable RNA (median value: 6.36 copies/ml
[5.91-6.86]) with 8/10 (80%) genotype 1 and 2/10 (20%)
genotype 3.
Discussion
This seroprevalence study of HBV and HCV was per-
formed at the Sainte Genevieve Health and Prevention
Center in order to update the data on chronic hepatitis
in the general population of Guadeloupe. Seroprevalence
was estimated at 1.41% for chronic HBV infection and
0.55% for HCV. The main risk factors were piercing,
familial exposure for HBV and nosocomial exposure for
HCV.
The Sainte Genevieve clinic is located in the main sub-
urb of Guadeloupe, home to one-third of the island’s
entire population. However, the estimated prevalence
rates may not accurately reflect the overall prevalence
of these infections on the island because the patient
population is not demographically representative. Per-
haps that periodically monitoring the prevalence of these
infections in this clinic population could be a simple and
effective approach for tracking HBV and HCV preva-
lence over time.
The only previous epidemiological study of HBV infec-
tion in Guadeloupe, reported by Fest et al. [2] in blood
donors during the period 1992–1993, found a prevalence
of more than 3.1%. The HBV prevalence of 1.4% seen
in the present study among the clinic patients from
2006 suggests that the frequency of HBV infection in
Guadeloupe may have decreased over time. This change
might reflect vaccination campaigns that were carried
out during this period. In a Guadeloupean study of a
teenage population, it was found that 76.2% were vacci-
nated against HBV [7]. The percentage of patients con-
sulting the center who were of low socioeconomic status
Gelu-Simeon et al. BMC Research Notes 2014, 7:55 Page 4 of 5
http://www.biomedcentral.com/1756-0500/7/55was estimated at 49% in 2006 and 45% in 2007, and
included the unemployed and those with minimal re-
sources. Although unemployment affected 27% of the
Guadeloupean population during the same period [8].
However, most patients residing in Guadeloupe are cov-
ered by health insurance that enables them to consult
physicians in a hospital or private medical center rather
than in a center run by the social security system. The
sexual transmission of HBV was not studied here but it
has been shown that in countries with a moderate preva-
lence of chronic HBV (1-5%), this rate is correlated to
that of sexually transmitted diseases [9]. Shaving by a
barber was described as the mode of HBV transmission
in four HBsAg positive patients. This transmission route
was also mentioned in an Italian study performed between
1997 and 2002 and which focused on beauty treatments
and the routes of HBV transmission [10]. It revealed a sta-
tistically significant relationship between barber shaving
and HBV transmission. It is possible that this factor lacked
significance in our study because of the small numbers
involved, but it would be interesting to include this factor
in a larger population.
In summary, this study provides the first data concerning
HBV prevalence in the general population of Guadeloupe,
and reached a level of nearly 1.5%.
Concerning chronic hepatitis C, we found an overall
prevalence of 0.55%. This low rate may be related to the
modes of transmission. Indeed, the main mode of trans-
mission was nosocomial in Guadeloupe (77.4%) and no
intravenous drug injection transmission was determined.
Most of the subjects were infected with HCV genotype 1,
probably related to the surgical transmission route, because
the link between genotype 1b and hospital-based trans-
mission is generally acknowledged [11]. Martial et al.
[12] also reported genotype 1 as being predominant in
Martinique HCV patients, essentially due to transmis-
sion via blood transfusions. Such a pattern of HCV
transmission is unique. Indeed, in the French study re-
ported by Meffre C et al., nearly 50% of HCV transmission
was found in intravenous drug users and only 15% was
transmitted nosocomially [13].
Conclusions
This is the first study of the prevalence of chronic hepa-
titis B and C to have been performed in the general
population of the French Caribbean island of Guadeloupe,
without any distinctions being made with respect to age,
gender or blood donor status. In addition to the high
prevalence of hepatitis B infection, some of the epidemio-
logical features of chronic hepatitis B and C, as well as
their modes of transmission, were relevant. It would be
useful to study these characteristics in a large Caribbean
cohort from the population affected by chronic hepatitis.
Concerted, island-wide efforts are necessary to reinforceprevention and control strategies to target HBV and im-
prove surveillance. In this way, it will be possible to moni-
tor hepatitis B infection and ensure the appropriate testing
and medical management of infected individuals. Such
measures would enable improvements to health practices
and prevention in this part of the world.
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